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Introduction: The benefit of surgery (trimodality therapy [TMT]) 
after chemoradiotherapy (CRT) for patients with stage III non–small-
cell lung cancer (NSCLC) is controversial, but nodal pathologic com-
plete response (N-PCR) is accepted as a strong predictor of overall 
survival (OS). We compared the outcomes of patients treated with 
TMT versus CRT, focusing on the importance of N-PCR.
Methods: Patients with stage III NSCLC treated with CRT or TMT 
from December 2004 through December 2012 were included; patients 
with N3 disease were excluded. Pathologic nodal response dichoto-
mized surgical patients into N-PCR versus residual nodal disease 
(RND) groups. Actuarial OS, progression-free survival (PFS), and dis-
tant metastasis-free survival (DMFS) were compared between patients 
treated with CRT and TMT and between CRT and N-PCR/RND.
Results: The cohort was composed of 138 patients (52% CRT and 48% 
TMT). The median OS was significantly higher after TMT than after 
CRT (81 versus 31.8 mo, p = 0.0068). This benefit was restricted to 
N-PCR (n = 50, 83.2 versus 31.8 mo, p = 0.0004), as RND (n = 19) 
experienced poor OS (16.1 mo). On multivariable analyses, N-PCR 
had superior OS (hazard ratio [HR], 0.38; p = 0.0012), PFS (HR, 0.42; 
p = 0.0005), and DMFS (HR, 0.42; p = 0.0007) compared with CRT. 
Conversely, there were trends for worse OS and PFS for RND versus 
CRT, although only inferior DMFS was significant (HR, 1.83; p = 0.04).
Conclusions: Surgical patients with complete nodal clearance experi-
enced superior survival, but those with RND fared no better than CRT 
alone. Mediastinal response may play an important role in the decision 
to proceed with surgical resection after CRT for stage III NSCLC.
Key Words: Non–small-cell lung cancer, Chemoradiotherapy, 
Trimodality therapy, Mediastinal staging.
(J Thorac Oncol. 2015;10: 1475–1480)
Concurrent chemoradiotherapy (CRT) is typically the essential component of definitive treatment for patients 
with stage III non–small-cell lung cancer (NSCLC).1 Indeed, 
the National Comprehensive Cancer Network gives definitive 
CRT alone a category 1 recommendation for most stage III 
NSCLC patients.2 The Intergroup 0139 trial showed that trimo-
dality therapy (TMT)—surgical resection following induction 
CRT—results in improved local control and progression-free 
survival (PFS) in appropriately selected patients with stage 
IIIA NSCLC.3 However, this disease control improvement did 
not translate into an overall survival (OS) benefit, possibly 
because of treatment-related morbidity in the surgical arm.
In the absence of randomized data that firmly support 
the addition of surgery, treatment choice is often a function of 
institutional and/or physician preference,4 especially because 
there are currently no reliable clinical, radiologic, or genomic 
tests that can establish the relative risk of local-only versus 
distant recurrence. Multiple prospective studies and retro-
spective series have shown that nodal pathologic complete 
response (N-PCR) after induction therapy is strongly prog-
nostic for improved survival outcomes.5–10 Patients with resid-
ual nodal disease (RND)—particularly positive mediastinal 
adenopathy—typically fare much worse. One may, therefore, 
question whether pathologic response should guide the deci-
sion to proceed with surgical resection.
At Rush University Medical Center, all patients with poten-
tially curable stage III NSCLC first undergo CRT and are evalu-
ated for resectability during and after treatment. Historically, 
we have aggressively pursued surgery after CRT given the first 
anticipated, and then proven, PFS benefit of resection. Although 
most patients with stage III disease were ultimately treated with 
definitive CRT, a sizeable percentage of individuals did undergo 
post-CRT resection. The objective of this retrospective study 
was to compare the outcomes of patients treated with TMT with 
those of patients treated with CRT alone, focusing on the dif-
ferential survival results as a function of pathologic nodal status.
PATIENTS AND METHODS
Patient Selection
The study population included all adult patients with 
stage III (N0–2) NSCLC treated with curative intent CRT with 
or without surgery at Rush University Medical Center initiated 
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between December 2004 and December 2012. Patients were 
excluded from the CRT cohort if they did not receive cura-
tive intent concurrent CRT (minimum 60 Gy). Patients treated 
with induction CRT (i.e., less than 60 Gy) but not proceed-
ing to surgery were excluded from the TMT cohort; additional 
exclusion criteria included a prior diagnosis of lung cancer or 
history of malignancy other than nonmelanoma skin cancer 
within 5 years of starting treatment. Institutional review board 
approval was obtained for this retrospective study.
Treatment
Details of radiation therapy and chemotherapy regimens 
have been reported previously by Gielda et al.11 Radiation 
therapy for all patients was delivered with a split course tech-
nique using three-dimensional conformal radiation therapy or 
intensity modulated radiotherapy to a target volume consist-
ing of the primary tumor and involved nodes plus a margin for 
setup error. Respiratory motion was assessed by fluoroscopy 
before 2006 and more recently with four-dimensional com-
puted tomography (CT) simulation. Treatment was given in 
1.8 to 2 Gy daily fractions. The total dose for patients receiv-
ing CRT alone was typically 60 to 64 Gy, whereas patients 
receiving TMT were typically treated to 44 to 46 Gy. All 
patients were treated with platinum-based chemotherapy regi-
mens. Most patients received carboplatin and paclitaxel, but 
after 2008, patients with non–squamous-cell carcinoma typi-
cally received carboplatin and pemetrexed. Among the TMT 
cohort, the decision to pursue this treatment paradigm was 
made in a multidisciplinary setting before any oncologic treat-
ment, and surgeons verified subsequent resectability based on 
clinical assessment and repeat chest CT after the delivery of 
neoadjuvant CRT. All patients underwent anatomical resec-
tion (lobectomy, bilobectomy, or pneumonectomy) approxi-
mately 4 to 6 weeks after induction CRT.
Posttreatment Evaluation
Radiation and medical oncologists performed clinical 
and radiographic follow-up, and surgeons also followed those 
patients treated with TMT. Chest CT was usually performed 
approximately 4 to 6 weeks after the end of definitive treat-
ment. Surveillance then consisted of chest CT every 3 months 
for the first 2 years, and semiannually thereafter. Positron-
emission tomography (PET)–CT was usually performed for 
further evaluation of suspicious findings on CT.
Data Collection
Patients were identified through a departmental data-
base. Demographic, disease, and treatment characteristics 
were recorded from the electronic medical record. Findings 
on surveillance imaging of abnormal-appearing or enlarged 
nodes, growth of the primary lesion, or development of dis-
tant metastases were usually confirmed with short-interval 
reimaging (chest CT or PET–CT) or by biopsy before ini-
tiation of salvage or palliative therapies. If recurrence was 
confirmed through these methods, the date of failure was 
recorded as the date of the initial abnormal surveillance scan. 
Locoregional recurrences included progression within the 
ipsilateral lung and nodal failures in the hilum, mediastinum, 
and supraclavicular fossa. Recurrences consistent with posi-
tive M-classification in the current American Joint Committee 
on Cancer 7 staging system, including new pleural lesions and 
malignant effusions, were classified as distant recurrences. 
Pathology reports from postinduction surgery were evaluated 
to determine response to neoadjuvant CRT. Response within 
the primary lesion was classified separately from response in 
the lymph nodes. Patients in the TMT cohort were dichoto-
mized as achieving N-PCR or RND.
Statistical Analysis
Differences in patient, disease, and treatment character-
istics between those treated with CRT versus TMT were tested 
using Fisher’s exact and χ2 tests. OS, PFS, and distant metas-
tasis-free survival (DMFS) were determined using Kaplan–
Meier statistics from date of diagnosis, and the log-rank test 
was used to analyze differences in survival curves. Gray’s test 
was used to assess differences in cumulative incidences of 
locoregional recurrence between the CRT cohort, the entire 
TMT cohort, and the two TMT subsets, with death serving as 
a competing risk.
Multivariable Cox regression analyses with stepwise 
selection were performed to compare adjusted survival out-
comes between three cohorts of patients: CRT versus TMT 
(all), CRT versus TMT (N-PCR), and CRT versus TMT 
(RND). Clinicopathologic variables included in the initial 
multivariable model were age, sex, overall stage, T-stage, 
N-stage, and histology. SAS version 9.2 (Cary, NC) was used 
for all statistical analyses.
RESULTS
Patient, Disease, and Treatment Characteristics
A total of 138 patients were included in this retrospective 
analysis. Patient and pretreatment disease characteristics are 
shown in Table 1. There were 72 patients (52%) who received 
CRT alone, and 66 patients received TMT (48%). There was 
a trend for more frequent PET–CT staging in patients treated 
with CRT alone (85% versus 74%, p = 0.14), whereas patho-
logic staging with mediastinoscopy was more usually done 
in those treated with TMT (70% versus 39%, p < 0.0001). 
The median radiotherapy doses in the CRT and TMT cohorts 
were 60 Gy (interquartile range [IQR], 60–60 Gy) and 45 Gy 
(IQR, 44–46 Gy), respectively. The clinical T-N stage distribu-
tion for CRT patients was T1–3 N2 (N = 36, 50%), T4 N0–1 
(N = 10, 14%), and T4 N2 (N = 26, 36%). The corresponding 
distribution for TMT patient was T1–3 N2 (N = 68, 88%), T4 
N0–1 (N = 4, 6%), and T4 N2 (N = 4, 6%).
The median length of hospitalization after surgery for 
the TMT patients was 5 days (IQR, 3–7 days). Postoperative 
cardiac complications were seen in six patients (9%): atrial 
fibrillation (N = 4), supraventricular tachycardia (N = 1), and 
nonfatal myocardial infarction (N = 1). Overall, serious com-
plications as a result of surgery were rare. Two patients (4%) 
developed pneumonia/empyema, and two patients (4%) were 
reintubated for hypoxia but were subsequently stabilized; all 
patients recovered from these acute events. Only one patient 
died within 30 days of surgery after experiencing asystole in 
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the immediate postoperative period. No patients died from 
radiotherapy complications.
Treatment Response at Time of Surgery
The median interval between the end of radiotherapy 
and surgery was 32 days (IQR, 26–40). Forty-seven of the 66 
patients (71%) in the TMT cohort had complete pathologic 
clearance of nodal disease in response to neoadjuvant CRT. 
Only 3 of 19 patients with RND had downstaging of nodal 
status, all from N2 to N1, but these patients were not differ-
entiated within the RND subset due to small numbers. Twenty 
patients (30%) had complete pathologic response of the pri-
mary tumor, whereas 24 patients (36%) had some decrease in 
T-stage noted at the time of surgery.
Survival
The median follow-up for surviving patients was 37 
months (IQR, 22.7–51.3 mo). Survival data are shown in 
Table 2. OS was significantly longer in patients treated with 
TMT versus CRT, with median survival times of 81 and 32 
months, and 3-year survival probabilities of 63% and 46%, 
respectively (p = 0.019). However, stratification based on 
pathologic nodal response showed that the improved out-
comes in the TMT cohort were restricted to those patients 
achieving N-PCR (Fig. 1). This subset had a median OS of 
83 months and 3-year survival probability of 73%, which 
was significantly better than those treated with CRT alone 
(p = 0.0009). In contrast, OS for RND patients was clearly 
inferior to that for the N-PCR cohort (16.1 mo and 35% at 3 
years, p = 0.0029), but did not differ significantly from those 
treated with CRT alone (p = 0.45).
When restricting the analysis to clinical N2 patients, 
there was improved survival in the TMT cohort (median OS 
80.6 versus 31.8 mo, log-rank p = 0.007). The significant 
difference was again strictly driven by the N-PCR popula-
tion (median OS 83.2 versus 31.8 mo for CRT, log-rank 
p < 0.0001).
There was a trend for patients treated with TMT to 
experience improved PFS (p = 0.06) and DMFS (p = 0.06), 
and subset analyses based on pathologic nodal response paral-
leled the OS results. Compared with the CRT cohort, the sub-
set achieving N-PCR had significantly improved 3-year PFS 
(56% versus 25%, p = 0.0013) and DMFS probabilities (56% 
versus 25%, p = 0.0011). Those with RND had 3-year PFS 
and DMFS probabilities of 11% for both endpoints, which 
were both significantly worse (p = 0.02 and 0.01 for PFS and 
DMFS, respectively) than the CRT cohort.
Multivariable Cox regression showed a persistent 
OS advantage in the TMT cohort (hazard ratio [HR], 0.56; 
p = 0.02) after adjusting for clinical nodal stage (Table 3). 
This survival gain was seen exclusively in the patients who 
experienced nodal clearance. When performing the regression 
with stratification by N-PCR status, patients with N-PCR had 
significantly improved OS (HR, 0.38; p = 0.0012), PFS (HR, 
TABLE 1.  Patient Characteristics
Characteristic Total CRT TMT P Value
Number 138 72 66 —
Age, yr, median (IQR) 65 (59,70) 68 (63,73) 65 (56,70) 0.03
Gender
  Male 69 (50%) 41 (57%) 28 (57%) 0.12
  Female 69 (50%) 31 (43%) 38 (42%)
TN stage
  T1–3 N2 94 (68%) 36 (50%) 58 (88%) 0.33
  T4 N0–1 14(10%) 10 (13%) 4 (6%)
  T4 N2 30 (22%) 26 (37%) 4 (6%)
Histology
  Adenocarcinoma 74 (54%) 37 (51%) 37 (56%) 0.68
  Squamous-cell carcinoma 59 (43%) 33 (46%) 26 (39%)
  NSCLC, unspecified 5 (3%) 2 (3%) 3 (5%)
ECOG performance status
  0–1 99 (72%) 65 (90%) 34 (52%) <0.0001
  ≥2 13 (9%) 7 (10%) 6 (9%)
  Unknown 26 (19%) 26 (39%)
Pretreatment PET–CT
  Yes 110 (80%) 61 (85%) 49 (74%) 0.14
  No 28 (20%) 11 (15%) 17 (26%)
Pretreatment mediastinoscopy
  Yes 74 (54%) 28 (39%) 46 (70%) <0.0001
  No 64 (46%) 44 (61%) 20 (30%)
CRT, chemoradiotherapy; TMT, trimodality therapy; IQR, interquartile range; ECOG, Eastern Cooperative Group; PET–CT, positron emission tomography–computed tomography; 
TN stage, clinical American Joint Committee on Cancer tumor and nodal stage, at diagnosis.
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0.42; p = 0.0005), and DMFS (HR, 0.42; p = 0.0007) com-
pared with individuals treated with CRT. Conversely, those 
with RND consistently had worse outcomes compared with 
the CRT cohort, although only inferior DMFS was statistically 
significant (HR, 1.82; p = 0.04).
Locoregional Recurrence
The cumulative incidences of locoregional recurrence 
are shown in Table 4. Locoregional recurrence outcomes 
were superior for the patients in the TMT cohort achiev-
ing N-PCR with 1-year, 3-year, and 5-year recurrence rates 
of 12%, 22%, and 30%, respectively. These results com-
pared favorably with recurrence rates of 27%, 50%, and 
55% in the CRT cohort (p = 0.0048). In contrast, the sur-
gical patients experiencing RND had the highest risk of 
locoregional recurrence, although the difference compared 
with the CRT cohort fell short of statistical significance 
(p = 0.0859).
TABLE 2.  Survival Outcomes and Univariable Analyses
Outcome
CRT TMT TMT, RND TMT, N-PCR
Median (mo) 3-year (%) Median (mo) 3-year (%) Median (mo) 3-year (%) Median (mo) 3-year (%)
OS 31.8 46 81a 63a 16.1 35 83.2a 73a
PFS 14.3 25 22.5 44 7.8a 11a 41a 56a
DMFS 18.7 25 23.3 45 8.6a 11a 62.3a 56a
aStatistical significance (p < 0.05) in comparison with CRT.
CRT, chemoradiotherapy; TMT, trimodality therapy; N-PCR, nodal pathologic complete response; RND, residual nodal disease; OS, overall survival; PFS, progression-free 
survival; DMFS, distant metastasis-free survival.
FIGURE 1.  Overall survival as a function of treatment and nodal response. TMT, trimodality therapy; N-PCR, nodal pathologic 
complete response; RND, residual nodal disease.
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DISCUSSION
Consistent with previous reports,5–10 our retrospec-
tive analysis found that N-PCR predicted for superior out-
comes in patients with stage III NSCLC treated with TMT. 
Dichotomization of TMT patients based on nodal pathologic 
response allowed comparison of each subset to patients treated 
with CRT alone. We found significantly better outcomes for 
those with N-PCR and equivalent or worse outcomes for the 
RND subset compared with CRT alone. Indeed, the finding 
of N-PCR at the time of surgery independently predicted for 
decreased risks of death from any cause, progression, and 
distant metastasis after the incorporation of known confound-
ers in multivariable analyses. In contrast, the RND subset of 
patients experienced significantly inferior DMFS in compar-
ison with patients receiving CRT alone, although the differ-
ences in OS and PFS did not reach statistical significance on 
adjusted analyses.
The association between improved survival and patho-
logic nodal response is well documented in other studies of 
surgery after neoadjuvant therapy for stage III NSCLC. The 
Intergroup 0139 trial reported a statistically significant differ-
ence in median OS of 34.4 months for N0 status versus 26.4 
months in those with N1–3 status at the time of surgery.3 The 
European Organization for Research and Treatment of Cancer 
(EORTC) conducted a randomized trial of neoadjuvant chemo-
therapy followed by either surgery or radiation for patients with 
stage IIIA (N2) disease, finding that median OS for ypN0–1 
status was 22.7 months versus 14.9 months for ypN2 (p = 0.04 
on multivariable analyses).12 Similarly, the German Lung 
Cancer Cooperative Group conducted exploratory post hoc 
analyses in a large randomized trial of patients with stage III 
NSCLC comparing two neoadjuvant regimens before surgery. 
Among those patients in both arms having complete resection 
of initial N2–3 disease, the median OS was 57.5 months in 
those with mediastinal downstaging to N0–1 disease and 25.1 
months in those with residual N2–3 disease (p = 0.003).13
One fundamental question in resectable stage III dis-
ease is whether the decision to proceed with surgical resection 
should depend on the pathologic nodal status after neoadju-
vant therapy. Although it is clear that patients with mediastinal 
downstaging experience superior survival in comparison with 
patients who do not, whether those most favorable patients 
gain additional benefit from surgery remains an open ques-
tion. The patients with favorable tumor biology may do well 
regardless of the intensity of local therapy, although our results 
suggest superb outcomes after TMT for this cohort. Patients 
with evidence of persistent primary tumor and nodal response 
may gain particular benefit from resection, as the primary 
oncologic gain from surgery is local-only control.3
On the other hand, it is also unknown whether patients 
with recalcitrant nodal disease should proceed with aggres-
sive surgery given their significantly poorer prognosis. The 
data presented in this article support an extremely cautious 
approach when considering resection in patients with residual 
mediastinal adenopathy, as their survival results are clearly 
not superior—and potentially worse—than outcomes in indi-
viduals treated with CRT alone.
Reliable and accurate mediastinal restaging after neoad-
juvant CRT remains a challenge in optimizing patient-specific 
decisions in this setting. Multiple studies have demonstrated 
a correlation between the amount of residual fluorodeoxyglu-
cose avidity and pathological response, but this association is 
much stronger for tumor rather than nodal response, the for-
mer of which is significantly less informative. For example, 
one prospective study of 93 patients using PET–CT for restag-
ing after neoadjuvant CRT showed mediastinal false-negative 
and false-positive rates of 20% and 25%, respectively, which 
are inadequate for decision making.14 Available methods for 
pathologic restaging include endobronchial and/or esopha-
geal ultrasonography with fine-needle aspiration and repeat 
mediastinoscopy. However, sensitivity of endoscopic nee-
dle biopsy for restaging has proven disappointing.15 Repeat 
TABLE 3.  Multivariate Analyses of Survival Outcomes
Predictor
OS PFS DMFS
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Treatment type
  CRT Ref 0.0015 Ref <0.0001 Ref <0.0001
  TMT, RND 1.28 (0.68–2.41) 0.44 1.71 (0.98–2.99) 0.06 1.83 (1.04–3.23) 0.04
  TMT, N-PCR 0.38 (0.21–0.68) 0.0012 0.42 (0.26–0.68) 0.0005 0.42 (0.25–0.69) 0.0007
N stage
  0 Ref 0.0313 Ref 0.0019 Ref 0.0096
  1 6.37 (1.51–26.9) 0.01 14.1 (3.25–61.0) 0.0004 9.53 (2.24–40.6) 0.02
  2 1.48 (0.59–3.72) 0.41 2.48 (1.0–6.17) 0.05 2.29 (0.92–5.72) 0.08
CRT, chemoradiotherapy; TMT, trimodality therapy; N-PCR, nodal pathologic complete response; RND, residual nodal disease; OS, overall survival; PFS, progression-free 
survival; DMFS, distant metastasis-free survival; HR, hazard ratio, CI, confidence interval.
TABLE 4.  Cumulative Incidence of Locoregional Recurrence
Time (yr)
TMT,  
RND (%)
TMT,  
N-PCR (%) CRT (%)
1 55 13 27
3 68 22 50
5 75 (p = 0.0859) 30 (p = 0.0048) 55
P value reflects comparison with CRT alone.
TMT, trimodality therapy; CRT, chemoradiotherapy; N-PCR, nodal pathologic 
complete response; RND, residual nodal disease.
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mediastinoscopy is often technically more difficult and less 
sensitive in comparison with the pretreatment setting due to 
fibrosis from neoadjuvant CRT and initial invasive staging.16 
Thus, our own clinical practice now trends toward pretreat-
ment endobronchial ultrasonography for confirmation of N2 
disease, reserving cervical mediastinoscopy for assessment 
after induction treatment.
This study has several limitations, several of which are 
inherent in any retrospective analysis. Selection bias and the 
potential influence of unknown confounders may have contrib-
uted to the differences in outcomes, especially considering that 
patients who ultimately went on to surgery were perceived at 
the time to gain benefit from it. For example, pathologic stag-
ing was not uniform between cohorts, and we were not able 
to quantify the volume or number of nodal stations involved 
at the time of initial or subsequent staging.17–19 Similarly, the 
general approach for follow-up and surveillance imaging was 
applied consistently in our practice for all stage III NSCLC 
patients, but one cannot exclude the possibility that subtle 
imbalances in restaging between CRT and TMT patients could 
partially explain progression outcomes. Another consideration 
is the use of split-course CRT at our institution. This regimen is 
an uncommon practice,11 and its use may limit the applicability 
of our data to patients receiving uninterrupted CRT.
Nevertheless, our results from a consistently treated 
cohort support the favorable survival outcomes after TMT for 
patients with a N-PCR. However, the survival outcomes in 
patients with RND were clearly not better than those treated 
with definitive CRT, and the latter population is obviously not 
exposed to the risk of surgical morbidity and mortality. Thus, as 
the sensitivity and specificity of mediastinal restaging modali-
ties improve, these data support using pathologic response as 
a key informant on the utility of resection, with evidence of 
residual disease serving as a criterion to defer surgery.
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